Seagen Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
- Conditions
- Interventions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT00529503
- Locations
- 🇺🇸
Sparrow Regional Cancer Center, Lansing, Michigan, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
🇦🇺St. Vincent's Hospital, Melbourne, Fitzroy, Victoria, Australia
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
- Conditions
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT00528333
- Locations
- 🇺🇸
Lakeland Regional Cancer Center, Lakeland, Florida, United States
🇺🇸Cancer Centers of the Carolinas, Greenville, South Carolina, United States
🇺🇸Gunderson Clinic, La Crosse, Wisconsin, United States
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00525447
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
- Conditions
- Interventions
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT00502112
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸St.Vincent's Comprehensive Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00435916
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
🇺🇸Charleston Hematology Oncology Associates, PA, Charleston, South Carolina, United States
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT00430846
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Washington University, St. Louis, Missouri, United States
🇺🇸University of Texas/MD Anderson Cancer Center, Houston, Texas, United States
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT00283114
- Locations
- 🇺🇸
Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States
🇺🇸University of Massachusetts Medical Center, Worcester, Massachusetts, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
A Safety Study in Patients With Chronic Lymphocytic Leukemia
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00283101
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00103779
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Cornell University, New York, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
- Conditions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00099255
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Stanford University, Stanford, California, United States